Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Beroni Begins Manufacture of Anti-Cancer Drug PENAO | Contract Pharma
Breaking News, Collaborations & Alliances

Beroni Begins Manufacture of Anti-Cancer Drug PENAO

Inks contract manufacturing deal with Aurigene Pharma Services.

Beroni Group, an Australia-based biopharmaceutical enterprise, said that PENAO Pty Ltd, its majority-owned, Sydney-based anti-cancer drug development company, has signed a drug manufacture contract with Aurigene Pharmaceutical Services, India, a subsidiary of Dr. Reddy’s Laboratories.
 
This next-generation adenine nucleotide translocase (ANT) inhibitor, PENAO, was shown to be safe and well-tolerated in a phase I clinical trial conducted in Australia where encouraging efficacy data was observed. In a second clinical trial to commence H1 2022, PENAO is planned to be administered as twice-weekly injections to patients with advanced solid tumors. It is going to be a dose-finding study that also investigates anti-tumor effects using morphological assessments including radiological responses, molecular imaging surrogates, and anti-proliferative effects.
 
“I am pleased that we are making significant progress in the development of the anti-cancer drug PENAO,” said Jacky Zhang, CEO, Beroni Group. “PENAO is a novel therapy targeting tumor cell mitochondria and could potentially have application in a wide range of cancers, including colorectal cancer, pancreatic cancer, ovarian cancer, liver cancer, etc. It is a potential treatment for cancers that are unresponsive to standard treatment, or for which no standard treatment exists.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters